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Racial Disparities in Clinically Significant Prostate Cancer
Treatment: The Potential Health Information
Technology Offers
Nina A. Bickell, Jenny J. Lin, Sarah R. Abramson, Gerald P. Hoke, William Oh, Simon J. Hall, Richard Stock, Kezhen Fei,
and Ann Scheck McAlearney
QUESTION ASKED: Are there racial dispar-
ities in thequalityof care for clinically significant
prostate cancer, and what are the reasons for
poorer quality care?
SUMMARY ANSWER: Treatment underuse
was low (4%).Most (73%) underuse cases were
system failures in which treatment was rec-
ommended but not received; 100% of men
experiencing system failures were black.
WHAT WE DID: We created evidence-based
quality measures for treating clinically signif-
icant prostate cancer. We identified all black
men and a random sample of age- and Gleason
score–matched white men and then abstracted
records and identified episodes of underuse.
We interviewed surgeons to classify reasons for
underuse.
MAIN RESULTS: Only 4% of men with
clinically significant prostate cancer experi-
enced underuse: 6% in black and 1% in white
men (P , .001). Thirty-eight percent of men
with system failures continued to receive care
at the same hospitals, offering ongoing op-
portunities to treat the cancer.
BIAS, CONFOUNDING FACTOR(S),
DRAWBACKS: Only two unaffiliated hospi-
tals serving an inner-city population were in-
cluded in this study, limiting generalizability.
Interviews, conducted with urologists as they
reviewed charts, occurred years after treatments
were given and are subject to recall bias. Patients’
views were not included.
REAL-LIFE IMPLICATIONS: While under-
use was low, the majority of cases were due to
systemfailures andoccurredexclusively inblack
men regardless of institution. System failures
occurred despite the presence of integrated
electronic medical records and health in-
formation technology capabilities at the hos-
pitals. Despite missing primary prostate cancer
treatment, a significant proportion of patients
continued to see physicians at their respective
hospital. Hospitals should harness their health
information technology to track care and in-
tervene when gaps in care are identified.
ReCAPs (Research
Contributions Abbreviated for
Print) provide a structured,
one-page summary of each
paper highlighting the main
ﬁndings and signiﬁcance of
the work. The full version of
the article is available online at
jop.ascopubs.org.
Copyright © 2017 by American Society of Clinical Oncology Volume 14 / Issue 1 / January 2018 n jop.ascopubs.org 37
Original Contribution CARE DELIVERY
Icahn School of Medicine at Mount Sinai;
Columbia University College of Physicians
and Surgeons, New York, NY; and The Ohio
State University, Columbus, OH
ASSOCIATED CONTENT
Appendix available online
DOI: https://doi.org/10.1200/JOP.
2017.025957; published online ahead
of print at jop.ascopubs.org on
December 1, 2017.
Racial Disparities in Clinically
Significant Prostate Cancer
Treatment: The Potential Health
Information Technology Offers
Nina A. Bickell, Jenny J. Lin, Sarah R. Abramson, Gerald P. Hoke,WilliamOh, Simon J. Hall,
Richard Stock, Kezhen Fei, and Ann Scheck McAlearney
Abstract
Purpose
Black men are more likely to die as a result of prostate cancer than white men, despite
effective treatments that improve survival for clinically signiﬁcant prostate cancer. We
undertook this study to identify gaps in prostate cancer care quality, racial disparities in
care, and underlying reasons for poorer quality care.
Methods
We identiﬁed all black men and random age-matched white men with Gleason scores$ 7
diagnosedbetween2006and2013at twourbanhospitals to determine rates of treatment
underuse. Underuse was deﬁned as not receiving primary surgery, cryotherapy, or
radiotherapy. We then interviewed treating physicians about the reasons for underuse.
Results
Of 359 black and 282 white men, only 25 (4%) experienced treatment underuse, and
23 (92%) of these were black. Most (78%) cases of underuse were due to system failures,
where treatment was recommended but not received; 38% of these men continued
receiving care at the hospitals. All men with treatment underuse due to system failures
were black.
Conclusion
Treatment rates of prostate cancer are high. Yet, racial disparities in rates and causes of
underuse remain. Only black men experienced system failures, a type of underuse
amenable to health information technology–based solutions. Institutions are missing
opportunities to use their health information technology capabilities to reduce disparities
in cancer care.
INTRODUCTION
In the United States, black men have the
highest rates of prostate cancer incidence
and mortality.1,2 Black men are 2.4 times
more likely than white men to die as a
result of prostate cancer. They are younger
at diagnosis,2,3 aremore likely to have poorly
differentiated tumors and to be treated
nonsurgically, and have poorer survival than
white men.4-6 Much of the racial disparity in
survival has been attributed to socioeco-
nomic factors and nonsurgical treatment,7,8
as well as to quality of care, rather than
being due to black men’s greater burden
of comorbidities.9,10 Yet, randomized trials
show equipoise in surgical versus nonsurgical
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treatment of clinically localized prostate cancer,11-13 and there are
conflicting findings regarding racial differences in prostate cancer
treatment receipt.4,14,15 Somereportworsequality,4,14 attributed to
differences in types and volume of hospitals and surgeons treating
black men, whereas others find no racial disparity.15 Despite the
plethora of studies describing disparate treatment rates between
blacks and whites,4,14,16-19 few describe reasons prostate cancer
treatment quality varies and whatmight be done to improve care.
To achieve significant reductions in cancer-related racial dis-
parities, hospitals need to know their treatment rates, racial dif-
ferences in treatments, and reasons for such differences. We
undertook this study at two hospitals, an academic and a mu-
nicipalhospital, serving theHarlemcommunity inNewYorkCity,
to assess possible racial differences in quality of care and explore
reasons for differences in care received.
METHODS
First, we worked with a Steering Committee of local experts in
prostate cancer to review the literature to decide on quality
measures. Next, we identified men with clinically significant
prostate cancer (Gleason score$ 7) who could benefit from
treatment and abstracted their records to assess care received.
We then interviewed the treating physicians of men who
experienced treatment underuse to identify possible reasons
for underuse and potential interventions to improve outcomes.
We contacted patients who experienced underuse for focus
groups; these data are presented elsewhere.20 Institutional Re-
view Board approval was obtained at both sites.
Developing Quality Measures and Defining Underuse
To develop quality measures of locally advanced prostate
cancer treatment, we conducted an evidence-based review of
randomized trials published in the prior 10 years.We included
phase III trialswithpatientswithGleasonscore$ 7 comparing
primary treatments of surgery (open, laparoscopic, or robotic-
assisted radical prostatectomy), radiotherapy (external beam
radiation therapy [EBRT] and/or brachytherapy), cryother-
apy, or androgen deprivation therapy (ADT) and reported
results of overallmortality, prostate cancer–specificmortality,
or biochemical failure. From 358 articles, 38 met criteria and
were reviewedwith a steering committee of experts in urology,
radiation therapy, medical oncology, general internal medi-
cine, and health services research (Appendix Table A1, online
only).We collected information on quality of life, and urinary,
bowel, and sexual function. Underuse was defined as: treat-
ment with ADTmonotherapy for patients treated after a 2009
seminal publication,21 or no prostatectomy, or no radio-
therapy (EBRT or brachytherapy), or no cryotherapy in men
with intermediate- or high-risk prostate cancers (Appendix,
online only). Definitive treatment included surgery, radio-
therapy (RT) with ADT, or cryotherapy.13 We wished to
include quality measures of RT dosing and ADT timing, but
there was inadequate documentation to reliably assess these
measures. Men with intermediate-risk cancer and low life
expectancy who received active surveillance, defined as
semiannual prostate-specific antigen (PSA) testing, were not
considered as underuse. Life expectancy was determined
using the Schonberg prognostic index.22
Case Identification
We chose to include only patients with clinically significant
disease (eg, Gleason score $ 7), because these are locally
advanced cancers for which treatment can improve survival;
we did not include low-risk cancers (eg, Gleason 6), because
there is inadequate evidence to show that treatment (v active
surveillance) improves survival.23 We identified all patients
with Gleason score 7 to 10 via pathology reports at the ac-
ademic tertiary referral center (2007 to 2012) and tumor
registry at the municipal hospital (2006 to 2013). There were
1,804 (350 black, 1,454 white) and 140 (135 black, 5 white)
patients at the respective sites. At the academic site, we
retained all black patients and randomly selected Gleason
score–matched white patients within 10-year age groups
(, 60, 60 to 69, 70 to 79,$ 80 years; n = 282), providing a final
yield of 641 patients (Fig 1). Patient race was based on ad-
ministrative reporting.24 Overall, we excluded 185 patients
because of previous cancer (n = 56), stage IV disease (n = 66),
poor prognosis (n = 9), diagnosis before 2006 (n = 21), or
consultation only (n = 33). Poor prognosis was based on
physician notes indicating that the patient had a poor
prognosis from other comorbidities.
We abstracted medical records for clinical characteristics,
includingcomorbidity,25 9-year Schonbergprognostic index22
(a validated tool predicting likelihood of living 9 years among
community-dwelling older adults), demographics, pathology,
PSA level, smoking, and descriptors of functional status. We
estimated each patient’s overall prognosis using the 9-year
Schonberg prognostic index. Given the nature of chart data,
former smoking status, self-rated health, and number of
overnight hospitalizations were not available. With these
missing data, ourmeasure of the 9-year Schonberg prognostic
index slightly overestimates patient life expectancy overall.
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There was no difference in missing data between younger and
oldermen or black andwhitemen.High 9-year life expectancy
was set at the median score of$ 84%. We used D’Amico risk
of cancer progression26: high risk included Gleason score 8 to
10, pretreatment PSA . 20, or stage $ IIc disease; in-
termediate risk includedGleason score 7, PSA between 10 and
20, or stage IIb disease.
We collected treatment data from inpatient and outpatient
records. When no treatment data were found, progress notes
were reviewed for evidenceof treatmentdelivered elsewhere to
seek missing treatment information.
Quantitative Analyses
We used bivariate t tests and x2 tests to compare patient
characteristics between the two racial groups. Multivariable
conditional logistic regression models determined which
clinical and demographic factors most affected the likelihood
of underuse in this matched sample.
Qualitative interviews
Three members of the research team (N.A.B., S.R.A., J.J.L.)
conducted semistructured interviews with the physicians
treating patients who experienced treatment underuse. In-
terviews, conducted while the treating physician reviewed
thepatients’ charts, focused on the physician’s general views
about treatment options, factors affecting patient decision
making, referrals and coordination across specialties, sug-
gestions to improve quality of prostate cancer care, and the
specifics of the underuse case. Interviews were audiotaped
and reviewed for common themes and reasons for treatment
underuse. Building on an a priori framework of reasons for
underuse,27 each case was reviewed and discussed, and a
primary reason for missed care was identified. The primary
reason for underuse was discussed with each physician as a
way of validating that the chosen underuse category fit with
their view of the cause of treatment underuse.
RESULTS
Hospital Characteristics
Both hospitals in this study are Disproportionate Share
Hospitals serving significant proportions of Medicaid pa-
tients.28 Surgeons at both sites perform radical prostatectomy,
although the municipal hospital did not have robotic surgery
capabilities. The academic site had RT and brachytherapy on
site; themunicipal hospital’s patients receivedRT at a network
hospital 1 mile away. Both had electronic medical records
(EMRs) with computerized order entry and the capability to
create best practice alerts. Significant numbers of patients at
the academic hospital but few from the municipal hospital
received care at affiliated private physician offices. The ma-
jority of private offices had some patient data in electronic
form. The academic referral center was in the process of
applying for accreditation by the Commission on Cancer; the
municipal hospital lost its accreditation in 2006. By 2013, both
hospitals were part of Accountable Care Organizations and
Medicaid Health Homes. At the time of this study, the mu-
nicipal hospital did not have patient portal capabilities; the
academic site had such portals, but they were not widely used.
Neither hospital had implemented a systematic approach to
monitor prostate cancer care performance.
Patient Characteristics
Five hundred seventy-five men at the academic center and
66men at themunicipal hospital were included in this study
(Fig 1). Of these 641 men, 56% were black and 84% had
high-risk cancer byD’Amico criteria (Table 1). The average
age was 60.5 years (6 8.7 years), and there were no dif-
ferences in age by race. Black men were more likely than
white men to have multiple comorbidities (32% v 11%;
P, .001), intermediate D’Amico cancer risk (19% v 11%;
P , .001), and low 9-year life expectancy (53% v 40%:
P, .001) andwere less likely to have commercial insurance
(66% v 88%; P , .001).
Physician Characteristics
Seventeen physicians treated the 25 patients who expe-
rience treatment underuse. Two urologists treating three
patients who experience treatment underuse were un-
reachable, resulting in 22 cases of underuse forwhich cause
could be categorized. The 15 treating physicians included
10 urologists, twomedical oncologists, and three radiation
oncologists. They had an average of 20.5 years (range, 4 to
30 years) in practice; 13% practiced at the municipal
hospital, 40% practiced at the academic hospital, and 47%
were in in private practice affiliated with the academic
hospital.
Underuse and Treatments Received
Initially, we identified 53 patients who experience treatment
underuse on the basis of chart abstraction data. After inter-
viewing physicians about the patients who experience
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treatment underuse, 28 were reclassified (13 were treated
elsewhere, fivehadmetastaticdiseaseatpresentation, fourhad
poor prognosis due to other conditions, fourwere treatedwith
ADT monotherapy before 2009, and two were clinical ex-
ceptions [e.g., advanced age]). There was no racial difference
in assessment of quality of life. Only 25 men of the 641 in-
cluded in this study experienced underuse, and 23 (92%)were
black. Sixteen(64%)were treatedat themunicipalhospitaland
nine at the academic center. Although underuse was low
overall (4%), black men were significantly more likely than
white men to experience underuse (6% v 1%; P , .001).
Surgery was the predominant primary treatment received.
White men were more likely than black men to undergo
surgery (91% v 69%; P , .001), and RT was more prevalent
among black than white men (21% v 7%; P , .001).
Multivariate Model
Multivariate conditional logistic model including age, life
expectancy, comorbidity, race, insurance, and prostate cancer
risk found that underuse was not associated with age (odds
ratio [OR], 0.6; 95%CI, 0.2 to1.8), low life expectancy (OR, 1.3;
95%CI, 0.4 to3.9), comorbidity (OR,1.6; 95%CI, 0.6 to4.1), or
black race (OR, 3.9; 95% CI, 0.8 to 36.5). Rather, commercial
insurance protected against underuse (OR, 0.09; 95% CI, 0.03
to 0.30) and intermediate D’Amico cancer risk (OR, 3.6; 95%
CI, 1.3 to 9.8) increased the risk of treatment underuse. A race-
insurance interactionwas not significant andwas not included
in the final model.
Qualitative Interview Findings
All patients who experienced treatment underuse had treat-
ment recommendedbut not received (Table 2). Seventy-seven
percent were classified as system failures—cases in which
treatment was recommended, the patient did not refuse
treatment, but treatment didnot ensue. Thesemenwere lost to
follow-up. Twenty-three percent of underuse cases were due
to patient refusal or financial barriers; half of these occurred at
the academic hospital.
System failures affected black men exclusively (16 of 16)
and were more common amongmen treated in the municipal
hospital (14 of 16). Themajority of system failures occurred as
men underwent work-ups to rule out metastasis or to assess
functional status and ability to undergo active treatment. Of
those who experienced system failures, 38% continued re-
ceiving medical care at the hospital. A small proportion of the
system failures (two of 16) included men who were slated to
undergo primary EBRT and were started on pre-RT ADT but
then did not go on to receive the primary radiation treatment.
Reviewing these episodes, the urologists believed it likely that
these patients were erroneously treated as patients with
metastatic disease who typically receive ongoing ADT if their
tumor responds, and their primary treatment, EBRT, never
occurred despite the fact that these men continued to receive
their ADT and medical care at that hospital. Of the two white
men who experienced treatment underuse, one experienced
financial barriers to treatment and the other’s physician de-
clined to be interviewed.
DISCUSSION
Overall,we foundratesof treatmentunderuse tobequite lowat
bothacademicandmunicipal hospitals.Although it seems that
blackmen experienced greater rates of underuse, this disparity
Municipal hospital patients
Assessed for eligibility
(N = 140)
  •  Previous cancer
  •  Metastatic cancer
  •  Poor prognosis
  •  Diagnosed before 2006
  •  Stage IV
  •  Consults only
Total ineligible
(n = 4)
(n = 25)
(n = 2)
(n = 20)
(n = 3)
(n = 20)
(n = 74)
Total cohort, all black
(n = 66)
Academic center patients
  •  Previous cancer
  •  Metastatic disease
  •  Poor prognosis
  •  Diagnosed before 2006
  •  Stage IV
  •  Consults only
Total ineligible
(n = 52)
(n = 36)
(n = 7)
(n = 1)
(n = 2)
(n = 13)
(n = 111)
Assessed for eligibility
(N = 686)
Total cohort
(N = 575)
Black
(n = 293; 51%)
White
(n = 282; 49%)
Fig 1. Patient selection.
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was related to insuranceandcancer risk.Menwith commercial
insurance weremore likely to go to the academic center; those
with public insurance were more likely to go to the municipal
hospital. Although both institutions had episodes of system
failures, such causes of underuse occurred more frequently at
the municipal than the academic hospital. Most concerning is
the concentration of system failures among black men, the
group with the highest mortality from prostate cancer. Men
treated at both the municipal and academic hospitals expe-
rienced system failures that potentially could have been
avoided had the institutions used their EMRs to identify these
gaps.BothinstitutionshadEMRsthatcontainedgapreportand
best practice alert capabilities, yet neither facility used these
capabilities to assess and ensure cancer care quality. The fact
Table 1. Patient Characteristics and Treatment Received by Race
Characteristic or Treatment Total (N = 641) Black (n = 359; 56%) White (n = 282; 44%) P
Age, years, mean 6 SD 60.5 6 8.7 60.9 6 9.2 60.0 6 8.0 .2
Comorbidity (. 0) 145 (23) 114 (32) 31 (11) , .001
Diabetic 90 (14) 74 (21) 16 (6) , .001
Obese* 148 (28) 84 (30) 64 (25) .2
PSA before diagnosis, mean 6 SD* 9.3 6 13.6 11.6 6 17.5 6.4 6 4.3 , .001
Gleason score .1440
7 564 (88) 309 (86) 255 (90)
8 34 (5) 23 (6) 11 (4)
$ 9 43 (7) 27 (8) 16 (6)
D’Amico .009
Intermediate 100 (16) 68 (19) 32 (11)
High 547 (84) 297 (81) 250 (88)
Stage* .0244
IIA 69 (12) 41 (14) 28 (10)
IIB 347 (62) 185 (64) 162 (59)
III 147 (26) 62 (22) 85 (31)
Smoking* 76 (13) 47 (15) 29 (11) .2
Insurance , .001
Commercial 485 (76) 237 (66) 248 (88)
Medicaid 50 (8) 49 (14) 1 (0.4)
Medicare 56 (9) 40 (11) 16 (6)
Self-pay 23 (4) 13 (4) 10 (4)
Unknown 27 (4) 20 (6) 7 (2)
Low 9-year life expectancy mortality risk (, 0.74) 305 (48) 191 (53) 114 (40) .001
Quality-of-life assessment 490 (76) 278 (78) 211 (75) .4
Primary treatments received , .001
Radical prostatectomy 505 (79) 247 (69) 258 (91)
Cryoablation 7 (1) 6 (2) 1 (0.4)
Brachytherapy 60 (9) 42 (12) 18 (6)
EBRT primary 34 (5) 31 (9) 3 (1)
ADT monotherapy 10 (2) 10 (3) 0
Underuse definitive treatment 25 (4) 23 (6) 2 (1) , .001
NOTE. Data presented as No. (%) except where indicated.
Abbreviations: ADT, androgen deprivation therapy; EBRT, external beam radiation therapy; PSA, prostate-specific antigen.
*Numbers may not add up because of missing data.
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thatseveralmencontinuedtoreceive theirmedicalcareat these
institutions reinforces criticalmissedopportunities to improve
cancer care and potentially reduce racial disparities in cancer
outcomes.
Wealso found that intermediate-risk cancerwasassociated
with underuse. Men with intermediate-risk cancer were more
likely to be older and, perhaps, more interested in active
surveillance than active treatment, although they were all
recommended to undergo active treatment given their higher-
risk status. Only one patient in our study was receiving active
surveillance. Although seemingly counterintuitive, black men
in our study were more likely than white men to have
intermediate-risk (v high-risk) prostate cancer. This finding
probably results from the large numbers of black men ex-
cluded because of metastatic disease at diagnosis.
Men with commercial insurance were more likely to be
treated. Decreasing proportions of uninsured patients because
of the Affordable Care Act29,30 portend well for men with
clinically significant prostate cancer. However, our findings
suggest that insurance will not completely solve racial dis-
parities in prostate cancer care.
Health care delivery systems must also change. Health
information technology (HIT) is being used to improve
population health and chronic disease management and to
monitor care performance.31 HIT registries such as the Rapid
Quality Reporting System require treatment reporting, but
their impact on racial disparities in cancer care is uncertain.32
OncologyMedicalHomes (OMH)andOncologyCareModels
use HIT to improve communication, coordination, and ac-
cess, with the goal of reducing variation and improving care at
reduced cost.33,34 Yet, the early OMHs served few black and
few Medicaid patients—the groups at greatest risk of system
failures.Of concern, evenwithin thesepromising andcommitted
environs, someOMHsites reportedchallenges implementing the
core tracking and coordinating requirements.34 It is still
unknown whether tying cancer treatment quality measures
to reimbursement will improve treatment rates and reduce
disparities. HIT-based interventions that target system
failures successfully eliminated racial disparities in breast
cancer treatment rates35 but have not been tested for prostate
cancer. Disturbingly, both the academic and municipal
hospitals in our study had electronic capability to monitor
gaps in performance, yet neither used this function in their
cancer care delivery—truly, a missed opportunity.
What can hospitals do to eliminate their missed oppor-
tunities to ensure all patientswith cancer receive optimal care?
Some safety-net hospitals are able to provide high-quality
cancer care despite their limited resources and can provide
useful models.35,36 Successful sites use HIT even when their
technology options are limited and assign an accountable
person to act on the data generated. Their EMRs have the
capacity to create gap reports, identify no-shows, and track
patients, and assigned staff then ensure follow-up for needed
treatments.35 Such gap reports can be used to monitor receipt
of primary therapy for men with elevated Gleason scores and
PSAs. Yet, this basic approach is not routinely implemented at
manyhospitals andmayhave significant survival implications.
Hospitals may wish to charge their Cancer Committees and
Quality personnel to work together to identify key measures
for gap report analyses and assign personnel to address
identified gaps.
Our study sample is small, consisting of just two hospitals
serving inner-cityNewYork.However, the hospitals represent
different facility types with different patient populations, al-
though both serve relatively large numbers of men with
prostate cancer. Although it is possible that a proportion of
those classified as experiencing treatment underuse were
treated, it is doubtful, because we tracked care wherever chart
Table 2. Reasons for Underuse of Effective Primary Treatment of Clinically Significant Prostate Cancer (N = 22)
Underuse Category Reason No. (%)
Treatment recommended
but not received, 21 (95%)
Nonadherence Financial barriers 1 (4.5)
Patient refusal 4 (18)
System failure Lost to follow-up 14 (64)
Lost within treatment 2 (9)
Non–guideline-concordant
treatment received, 1 (5%)
Favorable histology (small tumor) 1 (4.5)
Comorbidity or old age
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notesoroffice/clinical staff suggestedpatientsmayhavesought
other treatments and, with complete chart reviews, nearly
half of patients initially classified as experiencing treatment
underuse were reclassified as treated. We also reviewed all
potential underuse cases with the physicians and contacted
patients to ascertain their status and treatments. In some cases,
interviews with physicians occurred years after episodes of
underuse, and their responsesmayhave been affected by recall
bias.Tominimize thispotential confounder,wehadphysicians
review the patients’ charts before the interview, and they were
encouraged to refer to the chart during the interview to refresh
theirmemories. Patient race and hospital are highly correlated
in our small sample, making it impossible to separate the
impact of these key variables. We do not report previously
described differences in patient views of treatment and de-
cision making between men treated at the academic and
municipal hospitals.38 Although the Schonberg index is
typically used to helpmake screening decisions, not treatment
decisions,39,40 we used this tool because it is frequently used in
clinical settings, it provides a more objective measure of
patient prognosis, and our patients were all community
dwellers.
In conclusion, we found low rates of treatment underuse
amongmenwithclinically significantprostatecancer receiving
care at an academic referral center or amunicipal hospital. The
vast majority of underuse was due to system failures, which
affected only black men, regardless of institution. These
failures occurred despite the presence of integrated EMRs and
HIT capabilities to create gap reports in these organizations.
Hospitals need to harness their EMRs to track cancer care and
intervenewhentherearecaregaps.41Doing so has tremendous
potential to improve cancer care and to reduce disparities in
health outcomes.
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Appendix
Prostate Cancer Quality Measures for Men With Gleason Score $ 7
• Younger men (, 65 years old) or those with Gleason score 8 to 10, PSA. 10 ng/mL, or clinical stage T2c should undergo definitive
treatment (ie, radical prostatectomy [RP] or external beam radiation therapy [EBRT], not watchful waiting [WW]) within 12 months
of diagnosis.
• Exceptions: men with , 10-year life expectancy.
• RP and radiotherapy (RT) provide similar cancer control outcomes and should be offered to patients.
Table A1. Literature Review Search
Treatment
Category
Articles in
Search
Articles
After Limits
Imposed*
Articles
Excluded†
Articles
Used
RP v WW 358 20 17 3
RP v RT 2,275 30‡ 29 1
RP 6 adjuvant RT 3,036 59 55 4
Adjuvant v salvage
RT
214 143§ 141 2
RP 6 adjuvant ADT 176 7 6 1
RP 6 neoadjuvant
ADT
1,589 52 50 2
ADT 6 RT 1,641 85 83 2
RT dose 4,240 128 120 8
IMRT v 3D-CRT 548 400|| 397 3
RT 6 neoadjuvant
ADT
1,648 85¶ 81 4
RT 6 adjuvant ADT 1,648 85¶ 80 5
Brachytherapy BED 1,449 882§ 880 2
Pre/posttreatment
assessment
130 82§ 81 1
Abbreviations: ADT, androgen deprivation therapy; BED, biologic effective
dose; IMRT, intensity-modulated radiotherapy; RP, radical prostatectomy;
RT, radiotherapy; WW, watchful waiting.
*Unless otherwise indicated, limits are 10 years, randomized controlled trial,
humans (male), English language.
†Articles that do not include our demographic (ie, Gleason $ 7) or do not
directly report on the given category regarding patient outcomes, such as
biochemical progression-free survival, overall mortality, and prostate
cancer–specific mortality, are excluded
‡Expanding search to include comparative studies yielded one additional
article.
§Limits are 10 years, journal article, humans (male), English language.
||Limits are 2001 to present, journal article, humans (male), English language.
¶A google scholar search yielded two additional articles.
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• For patients undergoing RP with pathologic stage T3/4 (extracapsular extension, seminal vesicle invasion, or invasion of adjacent
structures) or positive surgical margins, adjuvant RT should be discussed or the patient should be referred to a radiation oncologist.
• Adjuvant androgen deprivation therapy (ADT) should not be received after RP (in patients without PSA. 5 ng/mL, two values. 2
ng/mL more than 3months apart with increasing tendency, three values . 1 ng/mL more than 3 months apart with increasing
tendency, or any clinical recurrence).
• Neoadjuvant ADT should not be received before RP.
• Primary ADT should not be used as monotherapy (apply only to patients treated after 2009).
• EBRT dose should be at least 74 Gy.
• Intensity-modulated radiotherapy or three-dimensional-conformal radiotherapy should be given with computed tomography
treatment planning (or equivalent imaging). If intensity-modulated radiotherapy is available, it is preferable.
• For patients who are at intermediate risk, RT should be accompanied by at least 4 months of (neoadjuvant and concurrent) ADT.
• For patients who are at high risk, RT should be accompanied by at least 2 years of ADT, with# 2 months given before the start of RT.
• If brachytherapy is used, postimplant dosimetry should be performed within 2 months of receiving the implants (30 days for
palladium-103 implants, 60 days for 125I implants).
• Pre- and post-treatment potency, urinary incontinence, and bowel function should be assessed for all patients. Pretreatment quality
of life should be evaluated at least once within 6 months of undergoing definitive treatment; post-treatment quality of life should be
evaluated at least once within the first 12 months after treatment.
• Because of conflicting studies, there is insufficient evidence to support or contraindicate cryoablation instead of EBRT.
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